EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Characterizing bone metastases and skeletal‐related events in patients with well‐differentiated neuroendocrine neoplasms utilizing 68 Gallium ‐ DOTATATE positron emission tomography

Tucker W Coston iD, Himil J Mahadevia iD, Marie M Plante, Alex Hochwald iD, Joseph M Accurso iD, Akash Sharma iD, Geoffrey B Johnson iD, Jonathan B Ashman, A Tuba Kendi, Mohamad Bassam Sonbol iD, Patrick W McGarrah iD, Timothy J Hobday und 2 weitere

Journal of Neuroendocrinology · 2026

DOI: 10.1111/jne.70301 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuroendocrinology, 2026. Verfasst von Tucker W Coston und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Duke Cancer Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Bone Neoplasms, Positron-Emission Tomography. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Endocyte, Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumors of neuroendocrine origin are a heterogenous group of related neoplasms which can arise from anywhere in the body. Neuroendocrine neoplasms (NENs) are categorized by site of origin, differentiation status and grade (Ki‐67 expression and/or mitotic rate), with significant prognostic variability accordingly. Historically, the prevalence of bone metastasis is reported to be 6%–12% based on “first generation” (i.e., 111 Indium pentetreotide [Octreoscan®]) somatostatin receptor imaging (SSRI). We conducted a retrospective cohort study including patients with well‐differentiated NENs to determine the clinical and imaging characteristics of osseous metastases when evaluated with higher‐sensitivity 68 Gallium‐DOTATATE positron emission tomography (PET) scans, as well as determining fracture prevalence in selected sub‐cohorts. We also developed a risk score analysis to assess risk of fracture in this cohort. Four hundred twenty‐four patients were identified for inclusion. The median age was 61 years. Most patients were asymptomatic (64%), had sclerotic lesions (77%), Krenning 4 (71%), and had >3 sites (69%) of osseous disease. A high proportion of patients had osseous metastases at sites with high risk for fracture, including vertebra (82%), pelvis (63%), and peri‐trochanteric femur (34%). Fifty‐seven patients (13%) in the entire cohort suffered a fracture. Fracture prevalence was significantly lower in small bowel neuroendocrine tumors (NETs, 7%) and Grades 1 and 2 disease (8% and 9%, respectively), with higher prevalence in pancreatic NETs, paragangliomas/pheochromocytomas, lung carcinoid, and Grade 3 disease (≥20% for each; p ‐values

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsBone NeoplasmsPositron-Emission TomographyHumansFemaleOrganometallic CompoundsMaleMiddle AgedRetrospective StudiesAgedAdultFractures, BoneAged, 80 and over

Stichwörter der Autor:innen

68Ga‐DOTATATEPET/CTbone metastasisneuroendocrine neoplasmneuroendocrine tumor

Substanzen

Organometallic Compoundsgallium Ga 68 dotatate

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Duke Cancer Center, Durham, North Carolina, USA.
  • Division of Hematology and Oncology, Mayo Clinic in Jacksonville, Jacksonville, Florida, USA.
  • Division of Hematology and Oncology, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, USA.
  • Division of Clinical Trials and Biostatistics, Mayo Clinic in Jacksonville, Jacksonville, Florida, USA.
  • Division of Nuclear Medicine, Mayo Clinic in Jacksonville, Jacksonville, Florida, USA.
  • Division of Nuclear Medicine, Mayo Clinic in Rochester, Rochester, Minnesota, USA.

ORCID-Profile: Tucker W Coston, Himil J Mahadevia, Alex Hochwald, Joseph M Accurso, Akash Sharma, Geoffrey B Johnson, Mohamad Bassam Sonbol, Patrick W McGarrah, Thorvardur R Halfdanarson, Jason S Starr

Förderung

  • Endocyte
  • Novartis

Zitieren

APA

Coston, T. W., Mahadevia, H. J., Plante, M. M., Hochwald, A., Accurso, J. M., Sharma, A., Johnson, G. B., Ashman, J. B., Kendi, A. T., Sonbol, M. B., McGarrah, P. W., Hobday, T. J., Halfdanarson, T. R., & Starr, J. S. (2026). Characterizing bone metastases and skeletal‐related events in patients with well‐differentiated neuroendocrine neoplasms utilizing 68 Gallium ‐ DOTATATE positron emission tomography. Journal of Neuroendocrinology. https://doi.org/10.1111/jne.70301

Vancouver

Coston TW, Mahadevia HJ, Plante MM, Hochwald A, Accurso JM, Sharma A, et al. Characterizing bone metastases and skeletal‐related events in patients with well‐differentiated neuroendocrine neoplasms utilizing 68 Gallium ‐ DOTATATE positron emission tomography. Journal of Neuroendocrinology. 2026. doi:10.1111/jne.70301

BibTeX
@article{Coston2026,
  author = {Coston, Tucker W and Mahadevia, Himil J and Plante, Marie M and Hochwald, Alex and Accurso, Joseph M and Sharma, Akash and Johnson, Geoffrey B and Ashman, Jonathan B and Kendi, A Tuba and Sonbol, Mohamad Bassam and McGarrah, Patrick W and Hobday, Timothy J and Halfdanarson, Thorvardur R and Starr, Jason S},
  title = {Characterizing bone metastases and skeletal‐related events in patients with well‐differentiated neuroendocrine neoplasms utilizing 68 Gallium ‐ DOTATATE positron emission tomography},
  journal = {Journal of Neuroendocrinology},
  year = {2026},
  doi = {10.1111/jne.70301}
}
Kostenlos starten →